Division of Cardiology, Department of Internal Medicine, Cardinal Massaia Hospital, Asti, Italy.
Division of Cardiology, Department of Medical Sciences, San Giovanni Battista Hospital, University of Turin, Turin, Italy.
Heart Rhythm. 2014 May;11(5):777-82. doi: 10.1016/j.hrthm.2014.02.018. Epub 2014 Feb 19.
The natural history of atrial fibrillation (AF) is characterized by gradual increase in duration and frequency of relapses until a definitive shift to permanent AF. Heart disease and comorbidities modulate AF progression. However, to date the influence of catheter ablation on AF evolution has rarely been investigated.
The purpose of this study was to identify long-term predictors of AF progression in a large cohort of patients undergoing AF transcatheter ablation (AFTCA).
A total of 889 patients (mean age 57 ± 11 years; 53.3% paroxysmal AF, 40.5% persistent AF, 6.2% long-standing AF) underwent AFTCA. All patients underwent pulmonary vein isolation, with linear lesions and complex fractionated atrial electrogram ablation reserved for patients with persistent/long-standing AF and/or confirmed structural heart disease.
After median follow-up of 64 months (range 41-84 years), AF progression despite AFTCA occurred in 57 cases (6.4%). However, AF progression was much more pronounced in patients with persistent (10%) or long-standing persistent AF (14.6%) than in those with paroxysmal AF (2.7%, P <.001). Furthermore, AF progression was more frequently reported in patients who presented with underlying comorbidities/cardiomyopathies (9.1%) than in those who presented with lone AF (29.9%, P <.001). At multivariate analysis, comorbidities/cardiomyopathies and baseline persistent/long-standing AF proved to be independent predictors of progression (odds ratio 11.3, 95% confidence interval 2.6-48.0, P <.001, and odds ratio 1.6, 95% confidence interval 1.2-2.1, P <.001, respectively).
The presence of comorbidities/cardiomyopathies and persistent/long-standing AF seem to predict AF progression in patients undergoing AFTCA. Performing AFTCA in the paroxysmal phase of the arrhythmia may reduce progression of AF to its permanent form.
心房颤动(AF)的自然病程表现为发作持续时间和频率逐渐增加,直至最终转变为永久性 AF。心脏病和合并症可调节 AF 的进展。然而,迄今为止,导管消融对 AF 演变的影响很少被研究。
本研究旨在确定接受 AF 经导管消融(AFTCA)治疗的大型患者队列中 AF 进展的长期预测因素。
共 889 例患者(平均年龄 57 ± 11 岁;阵发性 AF 53.3%,持续性 AF 40.5%,长程持续性 AF 6.2%)接受 AFTCA。所有患者均接受肺静脉隔离,对于持续性/长程持续性 AF 和/或有结构性心脏病确诊的患者,保留线性病变和复杂碎裂心房电图消融。
中位随访 64 个月(范围 41-84 年)后,57 例(6.4%)发生 AFTCA 后 AF 进展。然而,持续性 AF(10%)或长程持续性 AF(14.6%)患者的 AF 进展明显更为显著,而非阵发性 AF 患者(2.7%,P<.001)。此外,与孤立性 AF 患者(29.9%,P<.001)相比,有基础合并症/心肌病的患者更常报告 AF 进展(9.1%)。多变量分析显示,合并症/心肌病和基线持续性/长程持续性 AF 是进展的独立预测因素(比值比 11.3,95%置信区间 2.6-48.0,P<.001,和比值比 1.6,95%置信区间 1.2-2.1,P<.001)。
合并症/心肌病和持续性/长程持续性 AF 的存在似乎可预测接受 AFTCA 的患者的 AF 进展。在心律失常的阵发性阶段进行 AFTCA 可能会降低 AF 进展为永久性的可能性。